Table 3.
Probability and ranking of Bayesian network meta-analysis of primary outcome indicators of each targeted small-molecule drug
| Interventions | SRI-4 response | BICLA response | Adverse reactions | |||
|---|---|---|---|---|---|---|
| SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
| Baricitinib(JAKs) | 0.38 | 6 | 0.40 | 3 | 0.61 | 4 |
| Deucravacitinib(JAKs) | 0.91 | 1 | 0.98 | 1 | 0.59 | 5 |
| Evobrutinib(BTK) | 0.43 | 5 | / | / | 0.44 | 6 |
| Fenebrutinib(BTK) | 0.45 | 3 | 0.56 | 2 | 0.30 | 8 |
| Iberdomide(Cereblon) | 0.79 | 2 | / | / | 0.13 | 10 |
| Cenerimod(S1PR1) | / | / | / | / | 0.93 | 1 |
| Filgotinib(JAKs) | / | / | / | / | 0.73 | 2 |
| GSK2586184(JAKs) | / | / | / | / | 0.29 | 9 |
| Lanraplenib(SYK) | / | / | / | / | 0.33 | 7 |
| Placebo | 0.43 | 4 | 0.07 | 4 | 0.66 | 3 |